I
nflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), are life-long, relapsing conditions affecting primarily the gastrointestinal tract of young adults. Unlike UC, intestinal inflammation in CD is transmural, often associated with luminal narrowing and stricture formation caused by excessive extracellular matrix (ECM) deposition. 1 Current therapies can relieve inflammation in CD, but do not alter the natural history of the disease or its progression to intestinal fibrosis and obstruction that often results in bowel resection. 2, 3 Unfortunately, surgery does not prevent the recurrence of bowel inflammation or the ECM changes that cause fibrosis and stenosis. 4 Animal models have greatly advanced our understanding of the mechanisms of gut inflammation. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Such models, however, have focused almost exclusively on the immunemediated mucosal inflammation with little attention to chronic disease and intestinal fibrosis. Models that reproduce transmural inflammation and the associated chronic changes in ECM as seen in CD are therefore required.
The hapten 2, 4, 6-trinitrobenzenesulfonic acid (TNBS), administered as an enema, originally was used in rats to induce chronic intestinal inflammation. 16 In the mouse, when mucosal epithelial integrity is disrupted by a concomitant administration of ethanol, the contact-sensitizing hapten crosses into the colonic mu-cosa where it induces a Th1-like delayed hypersensitivity response. 14, 17 This model, maintained for 2-3 weeks, is used widely to investigate immune events underlying the acute inflammatory responses in the gut, and the resulting colitis usually is maximized by the administration of sublethal doses of TNBS. 17, 18 We developed and characterized a modified TNBSinduced murine model of colitis that leads to long-term, instead of the short-term, inflammatory changes that occur in the models described earlier. Our model features chronic intestinal inflammation combined with abundant collagen deposition and fibrogenic ECM changes that are stable for 4 weeks after TNBS treatment. The analysis of selected genes at both the transcript and protein levels is consistent with enhanced deposition of ECM and tissue remodeling. We further show that the antisense oligonucleotide for p65 nuclear factor B (NF-B) subunit used before in the short-term models to abrogate inflammation only, 19 given prophylactically in this study, prevented extensive fibrotic connective tissue deposition and blocked moderate to severe inflammation in our long-term chronic colitis model. Additionally, we show that the p65 NF-B antisense oligonucleotide given therapeutically to animals with established chronic colitis was able to resolve severe inflammation and fibrosis, although a small percentage of the mice still displayed moderate fibrosis.
Materials and Methods

Animals
Twelve-week-old female mice of the CD-1 strain, an outbred genetic background, and BALB/c inbred mice were used in this study (Charles River Laboratories Inc., Wilmington, MA). The outbred CD-1 strain was chosen because of their shown susceptibility to ECM changes. 20 Mice were housed and fed standard mouse chow and tap water ad libitum throughout the study following protocols approved by the Institutional Animal Care and Use Committee at Case Western Reserve University School of Medicine and the Johns Hopkins University School of Medicine.
Induction of Colonic Inflammation
BALB/c (model 1, Figure 1 ) and outbred CD-1 (models 1-3, Figure 1 ), anesthetized by an intramuscular injection of ketamine HCl 50 mg/mL, xilazine HCl 20 mg/mL, and acepromazine 10 mg/mL in sterile water (0.04 mL) were randomized into control and treatment groups. The schedule of TNBS (Sigma Chemical Co., St. Louis, MO) in 30% to 45% ethanol enemas administered as described earlier is outlined for the 3 models used here in Figure 1 . Control mice were given 0.1 mL water or saline or 30% ethanol alone. All mice were examined 4 times a week for signs of colitis including weight loss, diarrhea, rectal bleeding, and prolapse as described earlier, 21 as well as signs of systemic inflammation such as piloerection, lethargy, and periorbital exudates. 22 For prophylactic (model 2, Figure 1B ) and therapeutic treatment (model 3, Figure 1B ) of chronic inflammation and fibrosis, the antisense phosphorothioate oligonucleotide to the murine p65 NF-B subunit was used as described earlier. 19 The CD-1 mouse strain was given weekly enemas as follows: (1) saline, (2) TNBS, (3) TNBS plus p65 NF-B antisense 5ЈGAAACAGATCGTCCATGGT3Ј, (4) TNBS plus control scrambled sequence oligonucleotide 5ЈGTACTACTCTGAG-CAAGGA3Ј. In model 2, TNBS enemas were given for 6 weeks, as described for model 1 and the oligonucleotide enemas (150 g in 0.1 mL water) were administered 1 day before each TNBS enema. In the therapeutic model 3, all conditions were as in model 2, except that the oligonucleotide treatments were given 1 day before the fifth and sixth TNBS enema. The mice were weighed every third day and killed for histology 2 weeks after the last TNBS and oligonucleotide treatment. Figure 2 ) and histology. Mice with moderate to severe inflammation (I) and fibrosis (F) were scored in histology sections of the colons (representative colon sections are shown in Figure 3 ). (B) In models 2 and 3, CD-1 mice were given TNBS as in Figure 1A for weeks 1-6 only. Mice were harvested 3 days after week 6 and at week 8. In the prophylactic model 2, an antisense oligonucleotide to the p65 NF-B subunit (150 g in 0.1 mL water) was given as an enema 1 day before the TNBS enema, every week for 6 weeks. A group received a control oligonucleotide in which the sequence of the antisense oligonucleotide was scrambled, another control group received saline enemas. In the therapeutic model 3, the same antisense oligonucleotide and the control oligonucleotide enemas were given on weeks 5 and 6, 1 day before the TNBS enema. Quantitative estimates of mice with mild, moderate, and severe inflammation and fibrosis for models 2 and 3 are shown in Figure 8 .
Tissue Processing
The colons were removed intact from the anus to the ileocecal junction, the length was measured, opened longitudinally, cleaned, and weighed. At macroscopic examination, the distal 5 cm of the TNBS-treated colons were indurated, edematous, thickened, with evidence of mucosal hemorrhage. Sections were taken from these involved regions for the following experiments: (1) formalin fixation and histologic examination; (2) fibroblast isolation; (3) hydroxyproline quantification; and (4) total RNA isolation.
Serial paraffin sections of the colon were stained with H&E to assess the degree of inflammation and with trichrome to detect connective tissue. A gastrointestinal pathologist with special expertise in intestinal inflammation (J.W.) examined each slide (model 1) in a blinded fashion. Models 2-3 were scored at the Johns Hopkins University (by S.C. and F.W.) in a blinded fashion. By using a modification of an established system for grading experimental colitis, the degree of inflammation was scored as absent, mild, moderate, or severe based on the density and extent of both the acute and chronic inflammatory infiltrate, loss of goblet cells, and bowel wall thickening. 21 An inflammatory infiltrate of low cellularity confined to the mucosa was scored as mild inflammation, and transmural inflammation with extension into the pericolonic adipose tissue with high cellularity was scored as severe. Intermediate changes were scored as moderate inflammation. Fibrosis was scored as mild, moderate, or severe, depending on the density and extent of trichrome-positive connective tissue staining and disruption of tissue architecture, compared with the water control mice.
Intestinal Mesenchymal Cell Isolation and Stimulation
Cells were isolated from control and TNBS-treated colonic tissue according to a previously reported technique. 23 Resulting cell monolayers were cultured in Dulbecco's minimal essential medium with 2% heat-inactivated fetal calf serum for 24 hours before stimulation, and then exposed to either recombinant human tumor necrosis factor ␣ (TNF-␣; 50 U/mL; R&D Systems, St. Paul, MN) or recombinant murine interferon ␥ (IFN-␥; 50 U/mL; PharMingen, San Diego, CA). The time of optimal induction, as judged by maximal messenger RNA (mRNA) expression levels, was determined by a time-response curve, ranging from 0 -24 hours after stimulation with TNF-␣ or IFN-␥ for both control and TNBS-treated mesenchymal cells. Optimal induction of mRNA expression by TNF-␣ and IFN-␥ expression was achieved after 12 and 6 hours' incubation, respectively.
Immunohistology
Formalin-fixed, paraffin-embedded sections were pretreated by deparaffin, antigen unmasking, and blocking with 1% H 2 O 2 for 10 minutes and 1.5% goat normal serum for 60 minutes. The specimens were incubated with primary antibody for 60 minutes. The primary antibodies used included monoclonal mouse anti-human ␣-smooth muscle actin (␣-SMA) (1:800), anti-human desmin (1:100) (both from DAKO Co., Carpinteria, CA), and anti-human vimentin (1:4000) (Zymed Laboratories Inc., South San Francisco, CA), all of which recognized the murine antigen as well. After washing, the sections were incubated with biotin-conjugated goat antimouse immunoglobulin G secondary antibody (1:200) for 60 minutes, then with avidin biotin enzyme reagent for 30 minutes, and then with DAB for 1-2 minutes and counterstained with Gill's (#2) hematoxylin (Sigma Chemical Co.) for 10 seconds. All steps were performed at room temperature. Between each step the sections were washed in phosphate-buffered saline (pH 7.4) 3 times, 5 minutes per wash.
mRNA Assessment by Semiquantitative Reverse-Transcription Polymerase Chain Reaction
Total RNA was isolated from fresh full-thickness colonic tissue as well as colonic mesenchymal cell monolayers by using the guanidinium thiocyanate method as described earlier. 24 One-microgram aliquots of total RNA were reverse transcribed to assay for Col1a2 and Col3a2, matrix metalloproteinase 1 (MMP-1), MMP-3, TIMP-1, transforming growth factor ␤1 (TGF-␤1), insulin-like growth factor 1 (IGF-1), TNF-␣, and IFN-␥ expression by reverse-transcription polymerase chain reaction in colonic tissue, and MMP-1, MMP-3, TIMP-1, TGF-␤1, and IGF-1 expression in cultured mesenchymal cells. The thermal cycle involved a 5 minute hot start at 94°C, followed by a sequence of 94°C for 30 seconds, annealing for 60 seconds, and extension at 72°C for 90 seconds. Primers, specific cycle numbers, and annealing temperatures used for each gene are shown in Table 1 . The resulting products were analyzed by agarose gel electrophoresis and quantified by densitometry on a Bio-Rad Gel Doc 1000 (BioRad, Hercules, CA). Results were standardized to ␤-actin.
Collagen Estimation by Hydroxyproline Quantification
Whole colonic tissue was hydrolyzed in 6 N HCl/0.5% phenol for 24 hours at 110°C in vacuo. After drying, appropriate aliquots were loaded into a Beckman 6300 amino acid analyzer (GMI, Inc., Albertville, MN) with the ordinary hydrolysate method altered by reducing the initial column temperature by 2°C to 48°C to enhance the separation of aspartate from hydroxyproline. 25 Hydroxyproline was expressed as a ratio to total amino acids measured in the tissue (Protein Sequencing Facility, University of Pittsburgh, Pittsburgh, PA).
Statistical Analysis
Results comparing control and TNBS-treated groups were analyzed using the analysis of variance Bonferroni-Dunn test for data not normally distributed, or the Student t test when results were consistent with normally distributed values.
Possible correlations among inflammatory cytokines (IFN-␥ and TNF-␣), profibrogenic growth factors (TGF-␤1 and IGF-1), MMPs, and TIMP expression were determined by the Pearson correlation. For all analyses, P Ͻ 0.05 was considered to be statistically significant.
Results
An Overview of the Models
The 3 models of TNBS treatment developed in this study are outlined in Figure 1 . The rationale for testing 3 variations of TNBS treatment and intervention with NF-B antisense is as follows. In the first model, model 1, we gave TNBS challenges for 6 weeks to establish chronic inflammation and then again at weeks 8 and 12 to ensure sustained inflammation, harvesting animals for evaluating inflammation and fibrosis 3 days after the TNBS challenges. Approximately 70% of the CD-1 mice showed severe inflammation 3 days after the second TNBS enema, indicating that this strain is amenable to TNBS-induced intestinal inflammation ( Figure  1A) . This model also was tested in a limited way in the BALB/c strain in which 60% of the mice showed severe inflammation and fibrosis by 6 weeks. As we gained more experience with this model, we felt that TNBS enemas at weeks 8 and 12 were unnecessary. Rather, it was more important to determine if fibrosis persisted after 6 weeks of TNBS treatment without further TNBS. Therefore, with the BALB/c strain in model 1 and the CD-1 mice in models 2 and 3, TNBS enemas were stopped after the first 6 weeks. At week 8, the BALB/c mice in model 1 showed persistence of severe inflammation in 60% of the mice and although fibrosis had resolved in a subset, 40% still showed severe fibrosis. In models 2 and 3 the 6 TNBS treatments were similar to model 1. In model 2, the NF-B antisense oligonucleotide was given as a prophylactic with every TNBS challenge, whereas in model 3 the antisense treatment was given after establishing chronic inflammation with 4 weekly TNBS treatments. The results of models 2 and 3 and representative histology from each model are discussed further later.
Macroscopic Changes
The mice lost weight 2-4 days after the initial TNBS enema, which they regained or exceeded before the next enema. Systemic manifestations included piloerection in 43%, lethargy in 50%, and diarrhea in 20% of mice after the second TNBS enema, which usually occurred on days 1-3 after an enema. At no stage were frank rectal bleeding, rectal prolapse, or periorbital exudates observed. Both strains showed 25% mortality between 3 and 6 weeks of TNBS treatment. Figure 2 shows representative examples of colons removed from waterand TNBS-treated (CD-1 strain) animals at week 8 (model 1). The TNBS-treated colons were thickened and edematous over the distal 4 -6 cm. No inflammatory changes were observed in the water/saline controls, whereas a minority (17%) of ethanol-alone control colons displayed mild to moderate colonic thickening and edema (data not shown).
Increased colonic to total body weight is used as an indication of colonic inflammation. 18 In model 1 in the TNBS-treated group, from weeks 2-12, showed in- ColIa2  5Ј-TCT CCA CTC TTC TAG TTC CT  55°C  250 bp  29  3Ј-TTG GGT CAT TTC CAC ATG C  ColI3a2  5Ј-CCC AGA ACA TTA CAT ACC A  51°C  376 bp  27  3Ј-ATT AAA ACA AGA TGA ACA C  MMP-1  5Ј-TGA ACA TCC ATC CCG TGA CC  55°C  484 bp  27  3Ј-ATC TCC ACC CCA CCC CCA CC  MMP-3  5Ј-CGA TGC TGC CAT TTC TAA TAA A  55°C  241 bp  27  3Ј-TAT GTG GGT CAC TTT TTT GGC A  TIMP-1  5Ј-TCG GGG CTC CTA GAG ACA CA  56°C  555 creased colonic:body weight compared with the control groups, suggesting persistent colonic inflammation (data not shown). Figure 3 shows cross-sections of the colon at distances 1-7 cm from the anus in CD-1 mice treated with TNBS at week 8 (model 1). Maximal, full-thickness inflammation was evident between the 4-to 6-cm segment: the mucosa and muscularis propria were focally destroyed and hyperplastic lymphoid follicles were prominent. The lumen was noticeably dilated beyond 7 cm, indicating a functional obstruction of the colon in the distal areas of inflammation and fibrosis. There were trichrome-positive diffused collagen deposits in the mucosa and submucosa in the 1-to 6-cm segment. Most importantly, in mice given weekly TNBS treatments for 6 weeks, without additional TNBS treatment, trichrome-stained collagen deposits were still evident 4 weeks after the sixth TNBS enema ( Figure 4A and B) . Total hydroxyproline was increased significantly in the week 8 TNBS-treated colons compared with the water controls (mean Ϯ SEM, 0.0069 Ϯ 0.00048 vs. 0.0055 Ϯ 0.00034; P ϭ 0.021; n ϭ 8), supporting the histologic observations that the level of collagen was increased in the TNBS-treated colons.
Changes in Colonic Tissue Architecture and Total Collagen
To determine if this model of chronic colitis and fibrosis could be developed in other mouse strains as well, we administered TNBS weekly to BALB/c mice (n ϭ 20) for 6 weeks, and examined these macroscopically and by histology after 2 additional weeks without further TNBS treatment (model 1, Figure 1 ). As seen in the CD-1 outbred strain, 2 weeks after the last TNBS enema, the BALB/c continued to show extensive trichrome-stained collagen deposits in the submucosa . Serial (1-7 cm from the anus) paraffinembedded sections were stained with H&E (left panels) to assess the degree of inflammation, or trichrome (right panels) to determine the level of connective tissue deposition. At 7 cm, the colon is markedly dilated but free of inflammation and without increase in collagen deposition. At 6 cm, moderate, predominately chronic, full-thickness inflammatory infiltrates are noted, which are associated with increased collagen deposits located predominantly in the superficial layers. At 4 cm, moderate to severe acute and chronic inflammation involving all layers of the bowel wall results in disruption of the muscularis propria and is associated with hyperplastic lymphoid follicles. At 2 cm, findings are similar to those observed at 6 cm. At 1 cm, less marked, chronic inflammatory infiltrates predominate in the superficial layers in association with moderately increased collagen deposits. All sections are shown at 20ϫ magnification.
( Figure 4D , asterisk) compared with minimal trichrome staining of the ethanol control ( Figure 4C ). (Table  2) . Although IFN-␥ mRNA was increased by 1.6-fold in the TNBS-treated colons, this change did not reach statistical significance (Table 2) . Of the ECM-related genes, Col1a2, MMP-1, and TIMP-1 mRNA levels were increased significantly in the TNBS-treated mice (Table  2) . We investigated possible correlations between the differentially expressed genes in the control vs. TNBS colon. No significant correlation was found between the levels of TNF-␣ with TGF-␤ or IGF-1 mRNA, or IFN-␥ with IGF-1 mRNA in control or colitic animals. Instead, there was a statistically significant positive correlation between IFN-␥ and TGF-␤ mRNA (r ϭ 0.755; P ϭ 0.019) in control animals, which was lost in the TNBS mice. Significant correlations between Col1a2 and MMP-3 mRNA (r ϭ 0.779; P ϭ 0.039), and Col3a2 and TIMP-1 mRNA (r ϭ 0.782; P ϭ 0.038) observed in control animals also were lost in colitic TNBS mice, which showed a statistically significant correlation between MMP-3 and TIMP-1 expression (r ϭ 0.586; P ϭ 0.017).
Phenotype of Colonic Mesenchymal Cells In Situ in TNBS-Treated Mice
Intestinal mesenchymal cells express multiple cytoskeletal proteins whose type and amount vary depending on the cell type, state of differentiation, and exposure to inflammatory mediators. 26, 27 Therefore, we investigated the expression of ␣-SMA, desmin, and vimentin to determine the cellular origin of the connective tissue. Compared with controls ( Figure 5A ), the submucosa in colonic cross-sections of the week 8 TNBS-treated mice from model 1 were weakly vimentin positive ( Figure 5B , asterisks). Immunostaining for ␣-SMA and desmin showed strong staining of the muscle layers in both the control and TNBS sections, as expected ( Figure 5C-F) . However, only sections from TNBS-treated colons showed ␣-SMA and desmin-positive cells within the submucosa (Figure 5D , arrows; 5F, arrowheads). These results indicated the presence of myofibroblasts within areas of collagen deposits in the submucosa of the week 8 TNBS samples.
Monolayers of colonic cells in culture displayed a different morphology depending on whether they were derived from water control or TNBS-treated mice (data not shown). Monolayers from control colons became confluent readily and showed typical morphology of slender juxtaposed nonoverlapping spindle cells. In contrast, monolayers from chronically inflamed colons failed to achieve confluency despite active replication, and individual cells showed remarkably thin and interlacing long bodies with prominent nuclei. Mesenchymal cells from both control and TNBS-treated colons expressed high levels of ␣-SMA and minimal levels of vimentin (data not shown).
Effect of TNF-␣ and IFN-␥ on MMP-1, MMP-3, IGF-1, TGF-␤1, and TIMP-1 mRNA Expression by Colonic Mesenchymal Cells
Mesenchymal cells produce much of the ECM proteins and enzymes that remodel them and play a pivotal role in fibrogenic tissue damage. Therefore, we examined selected functional characteristics of murine colonic fibroblasts cells derived from control and inflamed tissues. Cells isolated from the colon of control and TNBS-treated mice were exposed to TNF-␣ and IFN-␥ as representative cytokines known to be involved in experimental colitis. Both TNF-␣ and IFN-␥ increased MMP-1 and MMP-3 mRNA expression in these TNBS-treated and control colonic mesenchymal cells ( Figure 6 ). IGF-1 and TGF-␤1 expression, however, was not significantly altered by IFN-␥ or TNF-␣ in either mesenchymal cell cultures. Interestingly, in TNBS mesenchymal cells only, TIMP-1 mRNA expression was increased significantly, in response to IFN-␥ and TNF-␣ (both at P ϭ 0.039).
NF-B p65 Subunit Antisense Oligonucleotide Therapy
Previous studies have shown that the TNBS colitis model has a prominent CD4ϩ T-cell component that favors Th1-type cytokine production. 21 Recent studies further showed that local administration of antisense oligonucleotide to NF-B p65 down-regulated the expression of the p65 subunit of NF-B and abrogated colonic inflammation. 19 To determine whether this would be effective for minimizing fibrosis associated with chronic long-term inflammation, we tested the effects of p65 antisense oligonucleotide administered locally in 2 models. In the prophylactic model 2, the oligonucleotide treatment was given intrarectally 1 day before each TNBS treatment. The change in body weight was followed-up weekly for each experimental group (n ϭ 7-12 per group) and representative data are presented as change in body weight on day 3 after treatment compared with initial body weight on day 0 of each week. These results are shown for weeks 1, 3, and 5 ( Figure 7) . The saline controls (Figure 7 , solid bar) showed a consistent increase in body weight during weeks 1, 3, and 5. The TNBS-treated animals showed a consistent decrease in body weight each week. The TNBS-treated group that was given the NF-B antisense prophylaxis was the only one, other than the control saline group, that gained weight, at weeks 1 and 5, with no change at week 3 ( Figure 7A ). As in the TNBS group, the TNBS plus control oligonucleotide-treated mice lost body weight at each time point. In the therapeutic model 3, the antisense therapeutically treated group did not gain weight as the prophylactically treated group in model 2 ( Figure 7B ). The p65 antisense given prophylactically alleviated piloerection and lethargy (data not shown).
Extent of inflammation and fibrosis was assessed in these 2 models in animals harvested on week 8, 2 weeks after the last TNBS treatment. Percent of animals harboring mild, moderate, and severe inflammation and fibrosis are shown as bar graphs below representative histology sections of each group (Figure 8) . In model 2 ( Figure 8C and D) , the antisense given prophylactically was highly effective in preventing moderate and severe inflammation, compared with the TNBS-treated group (which showed moderate and severe inflammation in 33% and 22% of the mice, respectively) only 17% of the antisense-treated group still showed mild inflammation. Moderate and severe fibrosis seen in 45% and 22% of the TNBS group ( Figure 8B ) was absent in the antisense prophylaxis-treated group ( Figure 8C) , with only 33% of this group showing mild fibrosis. In model 3 ( Figure  8E and F) , the therapeutically treated group receiving the antisense treatment at weeks 5 and 6 of the TNBS regimen had mild inflammation in 43% of the animals, with 14% still showing signs of moderate fibrosis. Thus, in our long-term TNBS model, the abundant trichromepositive connective tissue build-up seen in the submucosa of TNBS-treated mice ( Figure 8B ) and those receiving TNBS plus control oligonucleotide ( Figure 8D ) was minimal in mice treated concomitantly with the NF-B antisense oligonucleotide (model 2, Figure 8C ). The therapeutic model 3 was effective in resolving moderate and severe inflammation, but less effective in clearing moderate fibrosis ( Figure 8E ).
Discussion
There is a strong yet poorly understood connection between chronic inflammation and fibrogenic changes in the intestine. Existing models of TNBS colitis based on 2 or 3 enemas only result in severe, but transient, inflammation that resolves over a short period of time. 18, 21, 28, 29 To induce long-term colonic inflammation and associated fibrosis, we modified the TNBS administration regimen to allow the development of chronic colitis and associated colonic fibrosis.
Early in the regimen, clinical signs of severe inflammation such as rectal bleeding and prolapse were rare and diarrhea was only transitory. In model 1, with weekly low doses of TNBS, the mice developed inflammation reflected by the increase in colon to body weight ratio. Acute and chronic inflammation, as well as increased connective tissue deposition, was evident by histologic examination. Increased trichrome staining, indicative of increased connective tissue, clearly was evident at week 6, but not at week 2. Most importantly, in mice that were not given any additional TNBS after 6 weeks, increased connective tissue staining persisted for 4 additional weeks. Model 1 applied to the BALB/c strain of mice also maintained colonic fibrosis for 2 additional weeks (based on our observation period) after the sixth TNBS treatment. This confirmed that the low-dose, long-term TNBS treatment that we have developed is capable of causing fibrosis that is maintained for 2-4 weeks without further TNBS induction. Also, our new model is not limited to the outbred strain of mice only, but is effective in the BALB/c inbred strain of mice as well. In fact, compared with the CD-1 strain, the BALB/c displayed higher levels of inflammation and fibrosis at the week 6 time point (mice harvested 3 days after the sixth TNBS treatment). At week 8, the percentage of mice with moderate/severe fibrosis was comparable in the 2 strains. The sequence of clinical and histologic events noted in this model better resembles active remodeling and fibrosis typically observed in human CD, 30, 31 and differs from the short-term inflammatory response seen in traditional TNBS-induced colitis used to study associated immune abnormalities. 18, 21 An increase in Col1a2 mRNA levels and an increase in hydroxyproline, a collagen-specific amino acid, indicate that total collagen had increased significantly in the TNBS-treated colons. Increased expression of the profibrogenic growth factors TGF-␤1 and IGF-1 in the TNBS-treated colons may be stimulating proliferation of mesenchymal cells that contribute to increased ECM synthesis as suggested by studies on IBD and on fibrosis in other systems. 26, [32] [33] [34] By immunohistology we showed that the submucosa, a primary site of increased collagen deposition in the TNBS-treated colon, contained ␣-SMA-positive, desmin-positive, and weakly vimentin-positive cells. Although the definition of myofibroblast is controversial, 35 this staining pattern strongly suggests the presence of mesenchymal myofibroblasts in the submucosa that are likely the source of the fibrotic tissue. Intestinal myofibroblasts also were implicated in fibrosis, in an earlier Lewis rat model, injected with bacterial cell wall lipopolysaccharides. 36 Mouse intestinal mesenchymal cells established from control and the TNBS groups were also ␣-SMA positive, but unlike the colonic sections were weakly positive for vimentin and desmin. Culture conditions often do not reflect tissue conditions in their entirety and may contribute to these apparent differences with the vimentin and desmin staining. However, high levels of ␣-SMA and low vimentin levels are consistent with a typical myofibroblast phenotype.
It is widely accepted that immune cell activation leads to nonimmune cell activation and profibrogenic ECM changes. 37, 38 Although mRNA levels may not reflect secretion or activity of cytokines, growth factors, and ECM proteins, we explored the cytokine/growth factor-ECM relationship by investigating their gene expression in colon tissues and colonic fibroblast cultures by RT-PCR. T-cell activation, a key event in intestinal inflammation, leads to increased IFN-␥ and TNF-␣. 39 -41 These are particularly prominent in the early stages of inflammation in IBD and in the TNBS models. These cytokines possibly are required for initiation of inflammation, but are not necessarily crucial for its maintenance. 18, 42 Thus, The mice were weighed each week on days 0 and 3 and the change in weight was calculated ([day 3 Ϫ day 0]/day 0) ϫ 100 for each animal. Mean for each treatment group Ϯ standard error of the mean are shown here for weeks 1, 3, and 5. Note that compared with the TNBS and control oligo group, which lost weight, the antisense-treated group is the only one, other than the saline group, that gained weight in model 2. In the therapeutic model 3, the saline group is the only one that gained weight each week.
in our long-term model 1, at the week 8 stage, there was only a modest increase in TNF-␣ message and no significant change in IFN-␥.
In a prior study, by microarray gene expression profiling, we found increased expression of genes associated with ECM deposition without a balanced increase in MMP production in CD but not UC, an observation that may explain why fibrosis and stenosis are seen commonly in CD. 43 In our TNBS models here we also noted increased mRNA levels for Col1a2 and only one of the MMPs, namely MMP-1. Additionally, TIMP-1, an inhibitor of proteolytic activities of MMPs, also was up-regulated, suggesting conditions that discourage remodeling and favor ECM deposition. Intestinal myofibroblasts from CD patients also were reported to express higher levels of TIMP-1. 44 We investigated the effectiveness of antisense NF-B oligonucleotide given intrarectally to not only alleviate inflammation, which has been shown in the past, 19 but also to reduce fibrogenic connective tissue changes associated with chronic inflammation in a prophylactic (model 2) and a therapeutic model (model 3). In model 2, TNBS-treated mice that were given the antisense oligonucleotide, macroscopic signs of the disease, namely piloerection, diarrhea, and significant weight loss, were minimal. More importantly, trichrome staining of colonic cross-sections showed lack of fibrogenic tissue architecture and abnormal collagen build-up. The therapeutic model 3, in which the antisense NF-B treatment was given twice (at weeks 5 and 6) after establishing inflammation and fibrosis with 4 prior TNBS treatments, was somewhat less effective than model 2 in resolving inflammation and fibrosis. Overall, the therapeutic model 3 was more effective in resolving inflammation than fibrosis. After the NF-B antisense treatment no animals showed moderate or severe inflammation, whereas 14% of the animals still showed moderate fibrosis. Thus, NF-B antisense treatment given prophylactically during development of chronic inflammation may provide an early block in the signaling cascade that leads to both inflammatory and downstream fibrogenic changes. Additionally, the promoters of several ECM genes have NF-B-responsive elements that may be regulated by NF-B in developing fibrosis. Blocking NF-B thus may down-regulate these ECM components and contribute toward lowering fibrogenic response. The antisense treatment given after inflammation and fibrosis was established is able to down-regulate inflammation well, and reduce severe fibrosis. Thus, our study shows that NF-B blockade by antisense oligonucleotides decreases intestinal inflammation and reduces fibrosis. On the other hand, the idea that defective NF-B signaling may lead to intestinal inflammation, as in CD associated with NOD2 variants, [45] [46] [47] may appear paradoxic. 48 At present, the mechanism by which NOD2 mutations increase susceptibility to CD is unknown. A possibility is that sensing of enteric bacterial components in the absence of physiologic NF-B activation may trigger gut inflammation through a NOD2-independent, inappropriate T-cell response. 49 In conclusion, we developed a novel murine model of chronic immune-mediated inflammation and associated fibrosis of the colon displaying certain features of CD. Histologically, CD and our long-term TNBS models show a full-thickness chronic inflammation associated with increased ECM deposition and distortion of colonic tissue architecture. The antisense NF-B treatment given prophylactically prevented weight loss and dramatically reduced TNBS-induced inflammation and fibrosis. Given twice therapeutically after establishment of inflammation and fibrosis, the antisense treatment resolved inflammation well and reduced the number of animals with moderate/severe fibrosis, but was ineffective at preventing weight loss.
